Lung Cancer Non-small Cell Stage IV — Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy
Citation(s)
A Randomised, Open-label Phase III Trial Evaluating the Addition of Denosumab to Standard First-line Anticancer Treatment in Advanced NSCLC